December 16, 2024 06:20 AM EST

Roche terminates a Phase 3 Spark gene therapy in hemophilia A

Kyle LaHucik

Senior Reporter

Roche has officially discontinued a Phase 3 hemophilia A gene therapy from its Spark Therapeutics unit, a spokesperson for the Swiss pharma told Endpoints News …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Roche terminates a Phase 3 Spark gene therapy in hemophilia A

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

After CagriSema, eyes are on Lilly’s oral GLP-1 as next key obesity play

Regeneron buys London-based ocular biotech

A look at biotech's year of the megaround

CagriSema’s weight loss data disappointed. What does Novo do next?

Neumora's major depression drug flunks first of three Phase 3 trials

Florida car dealer joins insulin pricing fight against Eli Lilly, Sanofi

Roche ter­mi­nates a Phase 3 Spark gene ther­a­py in he­mo­phil­ia A

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

more like this

Af­ter Ca­griSe­ma, eyes are on Lil­ly’s oral GLP-1 as next key obe­si­ty play

Re­gen­eron buys Lon­don-based oc­u­lar biotech

A look at biotech's year of the megaround

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Neu­mora's ma­jor de­pres­sion drug flunks first of three Phase 3 tri­als

Flori­da car deal­er joins in­sulin pric­ing fight against Eli Lil­ly, Sanofi

Roche terminates a Phase 3 Spark gene therapy in hemophilia A

After CagriSema, eyes are on Lilly’s oral GLP-1 as next key obesity play

Regeneron buys London-based ocular biotech

CagriSema’s weight loss data disappointed. What does Novo do next?

Neumora's major depression drug flunks first of three Phase 3 trials

Florida car dealer joins insulin pricing fight against Eli Lilly, Sanofi